Non-alcoholic fatty liver disease (NAFLD), a representative metabolic liver
disorder induced by obesity, is characterized by excessive hepatic lipid accumulation,
elevated oxidative stress, and impaired mitochondrial function. These metabolic
abnormal...
Non-alcoholic fatty liver disease (NAFLD), a representative metabolic liver
disorder induced by obesity, is characterized by excessive hepatic lipid accumulation,
elevated oxidative stress, and impaired mitochondrial function. These metabolic
abnormalities are accompanied by increased lipogenesis and suppressed lipolysis in
adipose tissue and Liver tissue, leading to disrupted lipid homeostasis, inflammation,
and hepatic fibrosis. Gelidium amansii, a red algae traditionally used as a raw material
for agar, has recently attracted attention as a marine-derived functional ingredient due
to its diverse bioactive components. This study aimed to evaluate the anti-obesity and
anti-steatosis effects of Gelidium amansii extract (GAE) and elucidate its underlying
molecular mechanisms using high-fat diet (HFD)-induced obese mice and cellular
models. GAE administration significantly reduced body weight gain and white adipose
tissue hypertrophy, decreased hepatic triglyceride accumulation, and normalized serum
AST and ALT levels without nephrotoxicity. Histological analyses revealed that GAE
alleviated hepatic lipid droplet accumulation, inflammatory cell infiltration, and
hepatocellular ballooning. GAE downregulated SREBP-1c and FAS, while
upregulating PPARα and CPT1A, indicating inhibition of lipogenesis and enhancement
of fatty acid β-oxidation. Furthermore, GAE reduced lipid peroxidation markers (4-
HNE and MDA), increased antioxidant enzyme SOD1, and decreased IL-6 and TNF-α
expression, demonstrating its antioxidative and anti-inflammatory effects. In addition,
GAE restored mitochondrial biogenesis through activation of the LKB1–AMPK–
SIRT1–PGC-1α–NRF1–TFAM pathway and enhanced mitophagy via the
PINK1/Parkin/LC3B axis, improving mitochondrial quality control and mitochondrial
homeostasis. It also reactivated PI3K/AKT signaling and inhibited the TGFβ1/Smad2/3 pathway, thereby suppressing COL1A1 expression and collagen deposition.
Overall, GAE effectively ameliorates obesity-induced NAFLD by regulating lipid
metabolism, attenuating oxidative stress and inflammation, restoring mitochondrial
function, and inhibiting hepatic fibrosis. LC–MS/MS analysis identified Porphyra-334,
a mycosporine-like amino acid (MAA), as a major active compound contributing to
these protective effects, highlighting the potential of GAE as a marine-derived
functional ingredient for the prevention and management of metabolic liver diseases.